Marcus Carr, MD, PhD, founder ofHemodyne (Bethesda, Maryland), will joinNovo Nordisk(Bagsvaerd, Denmark), a world leader in diabetes care, as chief medical officer for North America. He will have the additional title of executive director for clinical research-hemostasis group for North America. Carr will be based at the Novo Nordisk North American headquarters in Princeton, New Jersey. As part of his agreement with Novo Nordisk, he will continue to serve on the board of Hemodyne until August 2006. Additionally, Carr will continue to provide consultation services to Hemodyne during this period. Hemodyne’s work with Novo Nordisk has revolved around Novo Nordisk’s flagship hemophilia drug, Novo 7, which has been shown in preliminary studies to be highly effective in treating hemorrhagic stroke and bleeding related to trauma. Hemodyne, focused on hemostasis and coagulation testing, recently launched its first product, the Hemostasis Analysis System, in the U.S. and Europe.